TET3 and hepatocellular carcinoma: The expression of TET3 in the training set of HCC patients was significantly lower than that in CHB patients (0.73 ± 0.21 vs. 0.98 ± 0.31), and the same was true in the validation set (0.71 ± 0.21 vs. 1.04 ± 0.27), with statistically significant differences (training: t = 4.39, P < 0.001; validation: t = 4.06, P < 0.001).